+

PE20060371A1 - Derivados de metastina en el tratamiento del cancer - Google Patents

Derivados de metastina en el tratamiento del cancer

Info

Publication number
PE20060371A1
PE20060371A1 PE2005000728A PE2005000728A PE20060371A1 PE 20060371 A1 PE20060371 A1 PE 20060371A1 PE 2005000728 A PE2005000728 A PE 2005000728A PE 2005000728 A PE2005000728 A PE 2005000728A PE 20060371 A1 PE20060371 A1 PE 20060371A1
Authority
PE
Peru
Prior art keywords
alkyl
substituted
aromatic
asn
phe
Prior art date
Application number
PE2005000728A
Other languages
English (en)
Inventor
Chieko Kitada
Taiji Asami
Naoki Nishizawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20060371A1 publication Critical patent/PE20060371A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE V ES A, B; n ES 0-1; W1 ES N, CH, O; W2 ES N, CH; Z1, Z3, Z5 Y Z7 SON CADA UNO H, ALQUILO C1-C3; Z4, Z6 Y Z8 SON CADA UNO H, O, S; R2 ES H, ALQUILO C1-C10 CICLICO LINEAL, ALQUILO C1-C8 SUSTITUIDO O NO CON CARBAMOILO, HIDROXILO, UN GRUPO CICLICO AROMATICO; R3 ES ALQUILO C1-C8 SUSTITUIDO O NO, ARALQUILO SUSTITUIDO O NO, ALQUILO C1-C4, ENTRE OTROS; R4 ES ALQUILO C1-C4 SUSTITUIDO O NO, HIDROCARBURO AROMATICO C6-C12, HETEROCICLO AROMATICO DE 5-14 MIEMBROS, ENTRE OTROS; Q1 ES ALQUILO C1-C4 SUSTITUIDO O NO CON HIDROCARBURO AROMATICO C6-C12, HETEROCICLICO AROMATICO DE 5-14 MIEMBROS, GRUPO CICLICO AROMATICO FUSIONADO DE C8-C14, ENTRE OTROS; Q2 ES CH2, NH, O SUSTITUIDOS O NO; Y ES -CONH-, -CSNH-, -CH2NH-, -NHCO-, ENTRE OTROS; Z9 ES H, O, S; P Y P' SON IGUALES O DIFERENTES Y SON H, RESIDUO DE AMINOACIDO OPCIONAL LIGADO EN FORMA CONTINUA O DISCONTINUA, HETEROCICLO AROMATICO FUSIONADO DE 5-14 MIEMBROS, ENTRE OTROS. SON PREFERIDOS: TYR-ASN-TRP-ASN-SER-PHE-GLY-LEU-ARG-PYA(4)-NH2; TYR-ASN-TRP-ASN-SER-PHE-GLY-LEU-ARG-PHE(2F)-NH2; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON SUPRESORES DE LA METASTASIS POR LO QUE SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2005000728A 2004-06-25 2005-06-23 Derivados de metastina en el tratamiento del cancer PE20060371A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004187671 2004-06-25
JP2004363311 2004-12-15

Publications (1)

Publication Number Publication Date
PE20060371A1 true PE20060371A1 (es) 2006-06-15

Family

ID=34971534

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009000637A PE20091567A1 (es) 2004-06-25 2005-06-23 Derivados de metastina en el tratamiento del cancer
PE2005000728A PE20060371A1 (es) 2004-06-25 2005-06-23 Derivados de metastina en el tratamiento del cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2009000637A PE20091567A1 (es) 2004-06-25 2005-06-23 Derivados de metastina en el tratamiento del cancer

Country Status (20)

Country Link
US (2) US7625869B2 (es)
EP (2) EP2113513B1 (es)
JP (3) JP4346650B2 (es)
CN (2) CN101845091A (es)
AR (1) AR049938A1 (es)
AU (1) AU2005257484A1 (es)
BR (1) BRPI0512397A (es)
CA (1) CA2571420A1 (es)
CL (1) CL2008003730A1 (es)
CR (1) CR8828A (es)
IL (1) IL179640A0 (es)
MA (1) MA28903B1 (es)
MX (1) MXPA06014206A (es)
NO (1) NO20065957L (es)
NZ (1) NZ552029A (es)
PE (2) PE20091567A1 (es)
RU (1) RU2006145886A (es)
SG (1) SG153865A1 (es)
TW (1) TW200607816A (es)
WO (1) WO2006001499A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
KR20050090420A (ko) 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
WO2004080479A1 (ja) 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 性腺機能改善剤
NZ550119A (en) 2004-04-08 2009-10-30 Biomatrica Inc Method for storing biological material in a dissolvable matrix
AU2005257484A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
ES2540886T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
EP2656836B1 (en) 2005-09-14 2017-07-26 MannKind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007125619A1 (ja) * 2006-04-26 2007-11-08 Kyoto University Ｇｐｒ５４アゴニスト活性を有する新規化合物
ITMI20061607A1 (it) 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
CN101528772B (zh) * 2006-10-25 2013-03-13 武田药品工业株式会社 Metastin衍生物及其用途
JPWO2009131191A1 (ja) * 2008-04-24 2011-08-25 武田薬品工業株式会社 メタスチン誘導体およびその用途
WO2009139298A1 (ja) * 2008-04-30 2009-11-19 国立大学法人京都大学 メタスチン誘導体およびその用途
EP2567723B1 (en) 2008-06-13 2021-01-20 MannKind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
RU2470681C2 (ru) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
PL2314609T3 (pl) * 2008-07-30 2017-07-31 Takeda Pharmaceutical Company Limited Pochodne metastyny i ich zastosowanie
MA32935B1 (fr) * 2008-12-29 2012-01-02 Takeda Pharmaceutical Agent prophylactique/therapeutique pour le cancer
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8716228B2 (en) 2009-05-27 2014-05-06 Yeda Research And Development Co. Ltd. GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
AR079657A1 (es) 2009-12-22 2012-02-08 Takeda Pharmaceutical Formulacion de liberacion sostenida
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
SG10201606220QA (en) 2011-04-01 2016-09-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013017631A1 (en) 2011-08-04 2013-02-07 Msd Oss B.V. Kisspeptide-pentasaccharide conjugates
CN103945859A (zh) * 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
EP2825548A4 (en) 2012-03-14 2016-02-24 Yeda Res & Dev MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
WO2014119753A1 (ja) * 2013-01-31 2014-08-07 学校法人 東京薬科大学 マイオスタチン阻害ペプチド
CN105451716A (zh) 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法
WO2015112703A1 (en) * 2014-01-22 2015-07-30 The Johns Hopkins University Compositions and methods for treating diabetes
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ，インク． 周囲温度における血小板の安定化
WO2017100212A1 (en) 2015-12-08 2017-06-15 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
IL311335A (en) 2016-09-30 2024-05-01 Sumitomo Pharma Switzerland Gmbh Methods for treating female infertility
JP7215755B2 (ja) 2017-07-05 2023-01-31 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド ペプチド類化合物、その使用及びそれを含む組成物
CN108752233B (zh) * 2018-07-18 2020-10-16 河北师范大学 小分子凝胶因子、凝胶材料及制备方法和应用
CN115515937A (zh) * 2020-05-08 2022-12-23 范因斯坦医学研究院 用于合成肽模拟物的二聚体

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
FR2488253A1 (fr) * 1980-08-08 1982-02-12 Roques Bernard Nouveaux peptides et leur application en therapeutique
IL74827A (en) * 1984-05-21 1989-06-30 Salk Inst For Biological Studi Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es) * 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0876349B1 (en) 1995-10-19 2002-09-11 Takeda Chemical Industries, Ltd. Quinoline derivatives as gnrh antagonists
JPH09169735A (ja) 1995-10-19 1997-06-30 Takeda Chem Ind Ltd キノリン誘導体、その製造法および用途
WO1997040071A1 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998039448A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
JP3822822B2 (ja) 1999-06-28 2006-09-20 ビーエーエスエフ アクチェンゲゼルシャフト 腫瘍の成長を予防する方法
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
CN1411509A (zh) 1999-12-17 2003-04-16 武田药品工业株式会社 Kiss－1肽的制造方法
JP2001231581A (ja) * 1999-12-17 2001-08-28 Takeda Chem Ind Ltd ＫｉＳＳ−１ペプチドの製造法
CZ20023567A3 (cs) 2000-03-29 2003-11-12 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
CA2404257A1 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Novel protein, dna thereof and process for producing the same
US7834141B1 (en) 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru) 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja) 2000-11-29 2003-01-29 Takeda Chem Ind Ltd 医薬組成物およびその製造法
JP2002320496A (ja) 2001-02-26 2002-11-05 Takeda Chem Ind Ltd 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ
WO2002085399A1 (en) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
US20040185525A1 (en) * 2001-05-17 2004-09-23 Osamu Nishimura Process for producing peptide
WO2003027149A1 (fr) 2001-09-19 2003-04-03 Takeda Chemical Industries, Ltd. Anticorps et utilisation de ce dernier
US20050176091A1 (en) * 2002-01-11 2005-08-11 Takao Yamada Process for producing kiss-1 peptide
JP2003300906A (ja) 2002-04-12 2003-10-21 Daiichi Fine Chemical Co Ltd がん転移抑制因子の安定化
CA2501556A1 (en) * 2002-10-09 2004-04-29 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
AU2003301569A1 (en) 2002-10-25 2004-05-13 Paradigm Therapeutics Limited Gpr54 knock-out mammals and screening methods using them
KR20050090420A (ko) * 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
JP4804714B2 (ja) 2002-12-26 2011-11-02 武田薬品工業株式会社 メタスチン誘導体およびその用途
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
KR100595364B1 (ko) 2003-02-20 2006-07-03 재단법인 목암생명공학연구소 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
WO2004080479A1 (ja) 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 性腺機能改善剤
EP1464652A1 (en) 2003-04-02 2004-10-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
US20050026224A1 (en) 2003-04-28 2005-02-03 Follettie Maximillian T. Methods and compositions for modulating G-protein coupled receptor 54
WO2004101747A2 (en) 2003-05-07 2004-11-25 The General Hospital Corporation Identification and use of gpr54 and its ligands for reproductive disorders and contraception
ATE399763T1 (de) 2003-05-30 2008-07-15 Prozymex As Proteasehemmer
RU2333221C2 (ru) 2003-11-03 2008-09-10 Бейцзин Санбио Байотек Ко., Лтд. Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
BRPI0318594B8 (pt) 2003-11-03 2021-05-25 Beijing Sunbio Biotech Co Ltd proteína recombinante que possui um efeito anticâncer, seu gene de codificação, seu uso, medicamento para tratar cânceres, vetor de expressão e microrganismo transgênico
WO2005095973A2 (en) 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
CA2562676A1 (en) 2004-04-23 2005-12-15 Applied Research Systems Ars Holding N.V. Use of gpcr54 ligands for the treatment of infertility
AU2005257484A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2007084211A2 (en) 2005-11-11 2007-07-26 The General Hospital Corporation Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
MX2008012055A (es) 2006-03-20 2008-10-02 Merck & Co Inc Agonistas del receptor de neuromedina u y usos de los mismos.
AU2007231553B2 (en) * 2006-03-28 2012-10-25 Molecular Discovery Systems Agent for the treatment of hormone-dependent disorders and uses thereof
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
JPWO2009044918A1 (ja) * 2007-10-05 2011-02-17 武田薬品工業株式会社 ニューロメジンｕ誘導体
JPWO2009131191A1 (ja) 2008-04-24 2011-08-25 武田薬品工業株式会社 メタスチン誘導体およびその用途
WO2010033224A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of kiss1 peptides

Also Published As

Publication number Publication date
AU2005257484A1 (en) 2006-01-05
BRPI0512397A (pt) 2008-03-04
EP2113513A3 (en) 2010-11-03
TW200607816A (en) 2006-03-01
NZ552029A (en) 2009-01-31
CR8828A (es) 2007-07-19
JP2008506632A (ja) 2008-03-06
CN101845091A (zh) 2010-09-29
EP1758932A2 (en) 2007-03-07
EP2113513B1 (en) 2016-05-18
US8778871B2 (en) 2014-07-15
JP2009024028A (ja) 2009-02-05
IL179640A0 (en) 2007-05-15
JP2009227687A (ja) 2009-10-08
CL2008003730A1 (es) 2009-05-04
US7625869B2 (en) 2009-12-01
JP4654284B2 (ja) 2011-03-16
CN101863971A (zh) 2010-10-20
WO2006001499A2 (en) 2006-01-05
EP2113513A2 (en) 2009-11-04
PE20091567A1 (es) 2009-11-03
US20090298765A1 (en) 2009-12-03
JP4346650B2 (ja) 2009-10-21
SG153865A1 (en) 2009-07-29
CA2571420A1 (en) 2006-01-05
WO2006001499A3 (en) 2006-03-02
MA28903B1 (fr) 2007-10-01
RU2006145886A (ru) 2008-06-27
AR049938A1 (es) 2006-09-13
MXPA06014206A (es) 2007-02-14
US20080312155A1 (en) 2008-12-18
NO20065957L (no) 2007-01-25

Similar Documents

Publication Publication Date Title
PE20060371A1 (es) Derivados de metastina en el tratamiento del cancer
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
PE20081441A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
PE20050015A1 (es) Derivados (3-oxo-morfolin-4-il)-fenilamida como inhibidores de factores de coagulacion y compuestos intermediarios en su preparacion
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
CO5690607A2 (es) Compuestos de piridina como inhibidores de dipeptidil peptidasa iv
CO5580768A2 (es) Derivados de 4,5-diariltiazol como ligandos cb-1
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
PE20000932A1 (es) Nuevos derivados sustituidos de pirazol
HRP20041042A2 (en) Novel substituted sulfamate anticonvulsant derivatives
AR076860A1 (es) Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
ATE518824T1 (de) Substituierte cyclohexylmethyl-derivate
MY157871A (en) Mapk/erk kinase inhibitors
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
AR047085A1 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad
HRP20050933A2 (en) Organic compounds
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
BRPI0413151A (pt) derivados de amino propanol
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载